Preliminary Safety and Efficacy Results From a First-in-Human Phase 1 Clinical Study of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic

• Post author:andrewkaretas
• Post published:November 9, 2026
• Post category:Dual/Scientific Publications

CAR T-Cell Therapy for Autoimmune Disease

Continue ReadingPreliminary Safety and Efficacy Results From a First-in-Human Phase 1 Clinical Study of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic

Off-the-shelf DLL3/CD70 dual CAR T cells with optimized site-specific integration for SCLC and neuroendocrine tumors

• Post author:andrewkaretas
• Post published:November 6, 2026
• Post category:DLL3/Scientific Publications

Continue ReadingOff-the-shelf DLL3/CD70 dual CAR T cells with optimized site-specific integration for SCLC and neuroendocrine tumors

Dr. Zachary Roberts discusses with Katie Couric Media how cutting-edge cancer therapy is being developed…

• Post author:andrewkaretas
• Post published:October 7, 2026
• Post category:Perspectives

Continue ReadingDr. Zachary Roberts discusses with Katie Couric Media how cutting-edge cancer therapy is being developed…

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

• Post author:andrewkaretas
• Post published:July 15, 2026
• Post category:CD70/Scientific Publications

Continue ReadingAllogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

John Carroll and Dr. Zachary Roberts discuss interim ALPHA3 findings and the future potential of allogeneic CAR T in LBCL.

• Post author:andrewkaretas
• Post published:May 22, 2026
• Post category:Perspectives

Continue ReadingJohn Carroll and Dr. Zachary Roberts discuss interim ALPHA3 findings and the future potential of allogeneic CAR T in LBCL.

Cytokine-Driven Divergence Between Allogeneic CAR-T Platforms

• Post author:andrewkaretas
• Post published:May 13, 2026
• Post category:PLATFORM/Scientific Publications

Continue ReadingCytokine-Driven Divergence Between Allogeneic CAR-T Platforms

Preclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myeloma

• Post author:andrewkaretas
• Post published:April 20, 2026
• Post category:BCMA/Scientific Publications

Continue ReadingPreclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myeloma

Allogene Therapeutics’ CAR-T Treatment Eliminates Residual Cancer Cells in B-cell Lymphoma Patients

• Post author:andrewkaretas
• Post published:April 13, 2026
• Post category:Perspectives

Continue ReadingAllogene Therapeutics’ CAR-T Treatment Eliminates Residual Cancer Cells in B-cell Lymphoma Patients

Could a New Alternative to a Bespoke Treatment Change the Future of Cancer Care?

• Post author:andrewkaretas
• Post published:March 5, 2026
• Post category:Perspectives

Continue ReadingCould a New Alternative to a Bespoke Treatment Change the Future of Cancer Care?

4: Statement of changes in beneficial ownership of securities

• Post author:andrewkaretas
• Post published:January 23, 2026
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading4: Statement of changes in beneficial ownership of securities